Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...

Rising rates of heart disease are claiming more lives each year, and researchers now believe a lesser-known body measure may offer clues about your future heart health. In recent findings from a large ...

Given the increasing prevalence of obesity and its significant impact on health, this study aimed to comprehensively assess ...

NIH Reports Social Factors Help Explain Worse Cardiovascular Health Among Adults in Rural vs. Urban Communities ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

In the United States, obesity is estimated to cause between 280,000 and 374,000 deaths each year and more than $170 billion ...

Obesity remains a global health crisis, often linked to serious diseases such as diabetes, heart disease, and fatty liver ...